Clinical trials for Prostate cancer

150 currently recruiting clinical trials
Phase 2 Prostate cancer #NCT05346848 #2023-509494-23-00
Localized None Systemic Treatment-Naive
Surgery Chemotherapy Radiotherapy Hormone therapy Internal Vectorised Radiotherapy (IVR)
1 recruiting site
Institut Bergonié
Phase 2 Prostate cancer #NCT02861573 #2023-506987-15-00
Adenocarcinoma Metastatic Castration-resistant 1 2 3 or more Chemotherapy Hormone therapy
Immunotherapy Immunotherapy
2 recruiting sites
Merck Sharp & Dohme LLC
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT05503797 #2024-513578-23-00
Locally Advanced Metastatic BRAF 1 2 3 or more
KRAS G12C KRAS non G12C NRAS HRAS Systemic Treatment-Naive
7 recruiting sites
Fore Biotherapeutics
Phase 2 Prostate cancer #NCT04536805
Biochemical recurrence None Surgery Radiotherapy Hormone therapy
5 recruiting sites
Institut de Cancérologie de l'Ouest
Phase 2 Prostate cancer #NCT06004661
Metastatic Castration-resistant PSMA PET Positive 1 Hormone therapy
Systemic Treatment-Naive Internal Vectorised Radiotherapy (IVR)
3 recruiting sites
Novartis
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer #NCT06923761 #2023-504845-30-00
Module 1 (Parties A, B, C, D) et module 2 (parties A et B) Tumeurs solides avancées
Locally Advanced Metastatic 1 2 3 or more
Systemic Treatment-Naive
7 recruiting sites
Grey Wolf Therapeutics
Phase 1 / Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer #NCT03093116 #2024-512606-25-00
Groupe 5
Metastatic NTRK-1/2/3 1 2 3 or more Immunotherapy Chemotherapy
Systemic Treatment-Naive Targeted therapy
4 recruiting sites
Turning Point Therapeutics, Inc.
Phase 1 / Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer #NCT03093116 #2024-512606-25-00
Groupe 6
Metastatic NTRK-1/2/3 1 2 3 or more Targeted therapy
Systemic Treatment-Naive
4 recruiting sites
Turning Point Therapeutics, Inc.
Phase 1 / Phase 2 Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer #NCT04585750 #2023-504251-27-00
Phase 2 autres tumeurs solides
Locally Advanced Metastatic Metastatic Castration-resistant TP53 1 2 3 or more
KRAS G12C KRAS non G12C Systemic Treatment-Naive
9 recruiting sites
PMV Pharmaceuticals, Inc